Israeli biotech Wize Pharma markets Israeli-developed LO2A eye drops for the treatment of ophthalmic disorders, including Dry Eye Syndrome. Wize is now to develop and trial the WP-REP1 gene therapy from Cleveland’s Copernicus for treating the rare eye disease Choroideremia.

http://wizepharma.investorroom.com/2019-09-09-Wize-Pharma-Enters-Exclusive-License-Agreement-for-Ophthalmic-Non-viral-Gene-Therapy-Technology

https://www.wizepharma.com/lo2a-eye-drops

https://www.youtube.com/watch?v=YBw3cO_YMsM